<DOC>
	<DOCNO>NCT01628055</DOCNO>
	<brief_summary>The purpose study evaluate ability IVIG affect rate progression brain ischemia , evidence neuroimaging . The result ongoing epidemiological study indicate patient primary immunodeficiency ( PID ) IVIG replacement therapy overall prevalence stroke 5 time less general population . Even strike absence stroke IVIG-treated PID patient 65 , general population age group stroke prevalence go 8.1 % . This suggest degree stroke protection correlate length IVIG treatment , since old PID patient treat IVIG significantly longer young one .</brief_summary>
	<brief_title>IVIG Acute Ischemic Stroke : A Pilot Study</brief_title>
	<detailed_description>Two pre-clinical study demonstrate effectiveness IVIG preparation improve clinical outcome stroke time provide evidence role complement fragment pathogenesis ischemia-induced brain damage . Scavenging active fragment IVIG likely mechanism beneficial effect . In one study CSL 's Privigen preparation use . Considering exhibited in-vitro scavenging ability pronounce several IVIG preparation , in-vivo scavenging capacity also proven relevant animal model , need test preparation stroke patient warrant . In addition , activation complement level activate fragment human seem correlate severity disease , make ideal therapeutic target .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Onset neurological symptom 4.5 8 hour 2 . Male Female age 45 75 year old 3 . Score 1015 point National Institutes Health Stroke Scale ( NIHSS ) clinical sign suggestive ischemic stroke 4 . Acute brain ischemia distinct penumbra ( least 20 % ) , measure magnetic resonance perfusion imaging ( PI ) diffusionweighted image ( DWI ) , territory middle cerebral artery , anterior cerebral artery , posterior cerebral artery hemispheric distribution 5 . Ability willingness provide inform consent comply study requirement procedures 1 . Eligibility acute thrombolytic ( rtPA ) treatment 2 . Normal brain MRI 3 . Transient ischemic attack rapidly improve neurological symptom 4 . Previous disability 5 . Hemorrhagic stroke brain MRI ( T2*/SWI ) 6 . Ongoing infection define clinical laboratory sign : evidencebased guideline follow detect infectious complication ( short , physical laboratory measure include WBC , ESR , hsCRP , PCT , fever , abnormal urine , chest Xray positive culture ) 7 . Diagnosis malignancy 8 . Known sensitivity ingredient study drug radiological contrast material 9 . Participation another clinical trial within past 30 day 10 . Stroke previous 3 month 11 . Chronic liver , kidney hematological disease 12 . Contraindications MRI Brain aneurysm clip , implanted neural stimulator , implanted cardiac pacemaker defibrillator , cochlear implant , ocular foreign body e.g . metal shaving , implant medical device : ( e.g . Swan Ganz catheter ) insulin pump , metal shrapnel bullet . 13 . Diabetes 14 . Hypertension 15 . Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>IVIg</keyword>
	<keyword>Acute Ischemic Stroke</keyword>
	<keyword>Stroke</keyword>
	<keyword>CVA</keyword>
	<keyword>Cerebrovascular Accident</keyword>
</DOC>